ADCT
Adc Therapeutics Sa
$0.9
Earnings Summary
Revenue | $19.28Mn |
Net Profits | $-47.12Mn |
Net Profit Margins | -244.34% |
Highlights
Adc Therapeutics Sa’s revenue jumped 11.52% since last year same period to $19.28Mn in the Q2 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated 1.53% jump in its revenue since last 3-months.
Adc Therapeutics Sa’s net profit jumped 26.81% since last year same period to $-47.12Mn in the Q2 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated 20.71% jump in its net profits since last 3-months.
Adc Therapeutics Sa’s net profit margin jumped 34.37% since last year same period to -244.34% in the Q2 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated 21.91% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Adc Therapeutics Sa post its latest quarter earnings
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Current Year | -0.86 |
Highlights
Adc Therapeutics Sa’s earning per share (EPS) estimates for the current quarter stand at -0.86 - a -561.54% fall from last quarter’s estimates.
Adc Therapeutics Sa’s earning per share (EPS) estimates for the current year stand at -0.86.
Key Ratios
Key ratios of the Adc Therapeutics Sa post its Q2 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Adc Therapeutics Sa’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2023. This indicates that the Adc Therapeutics Sa has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-06-30 | -0.86 | 0 | 100% |
₹0 US Stocks a/c Opening Fee